Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**BTHE + Huperzine A** appears to be a combination formula, with one component being **Huperzine A**. Huperzine A is a natural Lycopodium alkaloid isolated from Huperzia serrata and related species. It acts as a reversible acetylcholinesterase inhibitor, thereby increasing the levels of acetylcholine in the brain and is also a noncompetitive antagonist of the NMDA receptor. These actions are thought to contribute to its putative cognitive-enhancing effects and its use in traditional medicine and as a nootropic supplement for memory and concentration enhancement. Huperzine A is approved for use in China for Alzheimer's disease but is sold as a dietary supplement in other regions[1][5]. There is insufficient information available from the search results to determine what "BTHE" refers to specifically; it may be another herbal or supplemental ingredient or a brand-specific formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BTHE + Huperzine A.